Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 4;8(11):65. doi: 10.1038/s41389-019-0173-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a Drug combination of AMPC and MEK1/2 inhibitors. H1975 cells were seeded in 96-well plate and treated with AMPC, CI-1040/trametinib or the combination at different concentrations for 48 h. Fold change in cell viability is plotted. b Western blot analysis of p-ERK and ERK protein levels in cell lysates of H1975 treated with AMPC, CI-1040/Trametinib alone or the combination for 24 h. The levels of the total ERK was used as an input control. c Combination index (CI) and dose-reduction index (DRI) plots of AMPC and CI-1040/trametinib combination treatment in H1975 cells. d CI and DRI values at ED₅₀, ED₇₅, and ED₉₀ of AMPC and CI-1040/trametinib combination treatment in H1975 cells. e 3D Matrigel growth. H1975 cells were seeded in 5% FBS media containing 4% Matrigel and allowed to form colonies for 4 days prior to treatment with AMPC, CI-1040/trametinib or the combination for 7 days. Fold change in cell viability is plotted. Representative microscopic images of colonies formed by H1975 cells treated with AMPC, CI-1040/trametinib or the combination in 3D matrigel. Scale bar: 100 μm